Journal
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Volume 16, Issue 2, Pages 153-155Publisher
SPRINGER TOKYO
DOI: 10.1007/s10147-010-0116-z
Keywords
Collecting duct carcinoma; Sunitinib; Metastasis
Categories
Ask authors/readers for more resources
Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available